<table>
<thead>
<tr>
<th>Table No.</th>
<th>Title</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 1.1</td>
<td>Penetration enhancers used in transdermal products</td>
<td>25</td>
</tr>
<tr>
<td>Table 1.2</td>
<td>Marketed transdermal products</td>
<td>34</td>
</tr>
<tr>
<td>Table 5.1</td>
<td>List of material used</td>
<td>86</td>
</tr>
<tr>
<td>Table 5.2</td>
<td>List of equipments used</td>
<td>87</td>
</tr>
<tr>
<td>Table 6.1</td>
<td>Physical characteristics of fluoxetine</td>
<td>102</td>
</tr>
<tr>
<td>Table 6.2</td>
<td>Peaks in I.R. spectrum indicating various functional groups of fluoxetine</td>
<td>103</td>
</tr>
<tr>
<td>Table 6.3</td>
<td>Solubility of fluoxetine in different solvents</td>
<td>105</td>
</tr>
<tr>
<td>Table 6.4</td>
<td>Absorbance values of fluoxetine in chloroform at 227 nm</td>
<td>106</td>
</tr>
<tr>
<td>Table 6.5</td>
<td>Absorbance values of fluoxetine in 20% methanol in PBS pH 7.4 at 227 nm</td>
<td>107</td>
</tr>
<tr>
<td>Table 6.6</td>
<td>Composition of fluoxetine transdermal patches</td>
<td>111</td>
</tr>
<tr>
<td>Table 6.7</td>
<td>Physiochemical evaluation of fluoxetine transdermal Patches</td>
<td>114</td>
</tr>
<tr>
<td>Table 6.8</td>
<td><em>In vitro</em> dissolution profile of fluoxetine from transdermal patches containing EC/PVP in different proportion 4.5:0.5 (F1), 4:1 (F2), 2:1 (F3), 3:2 (F4) and 2:3 (F5)</td>
<td>118</td>
</tr>
<tr>
<td>Table 6.9</td>
<td><em>In vitro</em> dissolution profile of fluoxetine from transdermal patches containing EC/PVP (3:2) and different proportion of DMSO 2% (FD1), 5% (FD2) and 10% (FD3)</td>
<td>119</td>
</tr>
<tr>
<td>Table 6.10</td>
<td><em>In vitro</em> dissolution profile of fluoxetine from transdermal patches containing EC/PVP (3:2) and different proportion of tween-80 2% (FT1), 5% (FT2) and 10% (FT3)</td>
<td>120</td>
</tr>
<tr>
<td>Table 6.11</td>
<td><em>In vitro</em> dissolution profile of fluoxetine from transdermal patches containing EC/PVP (3:2) and different proportion of eucalyptus oil 2% (FE1), 5% (FE2) and 10% (FE3)</td>
<td>121</td>
</tr>
<tr>
<td>Table 6.12</td>
<td><em>In vitro</em> dissolution profile of fluoxetine from transdermal patches containing EC/PVP (3:2) and different proportion olive oil 2% (FO1), 5% (FO2) and 10% (FO3)</td>
<td>122</td>
</tr>
<tr>
<td>Table 6.13</td>
<td>Release kinetic of fluoxetine transdermal patches</td>
<td>124</td>
</tr>
<tr>
<td>Table</td>
<td>Description</td>
<td>Page</td>
</tr>
<tr>
<td>---------</td>
<td>------------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>6.14</td>
<td><em>In vitro</em> permeation studies of fluoxetine from transdermal patches containing EC/PVP (3:2) and without enhancer (F4), DMSO 10% (FD3), tween-80 2% (FT1), eucalyptus oil 10% (FE3), olive oil 5% (FO2)</td>
<td>127</td>
</tr>
<tr>
<td>6.15</td>
<td>Permeation parameters of <em>in vitro</em> studies of fluoxetine transdermal patches</td>
<td>129</td>
</tr>
<tr>
<td>6.16</td>
<td><em>In vivo</em> skin irritation studies of fluoxetine patch (FT1)</td>
<td>131</td>
</tr>
<tr>
<td>6.17</td>
<td>Effect of fluoxetine transdermal patch (FT1) and oral dose on immobility period in forced swim test</td>
<td>133</td>
</tr>
<tr>
<td>6.18</td>
<td>Effect of fluoxetine transdermal patch (FT1) and oral dose on immobility period in tail suspension test</td>
<td>134</td>
</tr>
</tbody>
</table>